Scholarlink

<p>Despite numerous studies on second-line therapies in metastatic pancreatic cancer, there is no randomized study evaluating the efficacy of gemcitabine plus nab-paclitaxel as a second-line treatment. This study aims to examine the efficacy of gemcitabine plus nab-paclitaxel in second-line therapy. In this retrospective study, a total of 218 patients from 23 centers were included. The primary endpoint was progression-free survival (PFS), secondary endpoints included overall survival (OS), treatment efficacy based on ECOG performance status (PS), and tumor marker (CEA, CA 19 − 9) levels. In the second-line treatment with gemcitabine plus nab-paclitaxel, the median PFS was 5.1 months (95% CI, 4.6 to 6.0), and the median OS was 8.6 months (95% CI, 7.3 to 10.0). Median PFS was 6.6 months in patients with normal CEA levels compared to 4.4 months in patients with high CEA levels (<i>P</i> = 0.01). Median PFS was 6 months in patients with ECOG PS 0–1 compared to 3.8 months in patients with PS 2 (<i>P</i> &lt; 0.01). This study demonstrates the contribution of gemcitabine plus nab-paclitaxel in both OS and PFS in second-line treatment of metastatic pancreatic cancer. It was found to be a good option especially for young patients with good ECOG PS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月5日

查看全文
  • Yasin Sezgin,
  • Oğur Karhan,
  • Mehmet Naci Aldemir,
  • Muslih Ürün,
  • Berrak Mermit Erçek,
  • Zuhat Urakcı,
  • Hayati Arvas,
  • Sezai Tunç,
  • Mehmet Erdem,
  • Halis Yerlikaya,
  • Serdar İleri,
  • İbrahim Aydın,
  • Abdurrahman Bicer,
  • Ahmet Ufuk Kömüroğlu,
  • Nargiz Majidova,
  • Savaş Gökçek,
  • Hacer Demir,
  • Sedat Yıldız,
  • Sinem Akbaş,
  • Esra Özen,
  • Burcu Ulaş Kahya,
  • Mürsel sali,
  • Hicran Anık,
  • Talat Aykut,
  • Murat Araz,
  • Ali Alkan,
  • Melike Özçelik,
  • Abudllah Sakin,
  • Musa Barış Aykan,
  • Mirmehdi Mehtıyev,
  • Bilgin Demir,
  • Mehmet Nuri Başer,
  • Müge Sönmez,
  • İlkay Gültürk,
  • Nilüver Avcı,
  • Semiha Urvay,
  • Mustafa Özgür Arıcı,
  • Mehmet Emin Kalender,
  • Mustafa Yıldırım,
  • Ali Alper Solmaz,
  • Mustafa Gürbüz,
  • Yakup Ergün

摘要

Despite numerous studies on second-line therapies in metastatic pancreatic cancer, there is no randomized study evaluating the efficacy of gemcitabine plus nab-paclitaxel as a second-line treatment. This study aims to examine the efficacy of gemcitabine plus nab-paclitaxel in second-line therapy. In this retrospective study, a total of 218 patients from 23 centers were included. The primary endpoint was progression-free survival (PFS), secondary endpoints included overall survival (OS), treatment efficacy based on ECOG performance status (PS), and tumor marker (CEA, CA 19 − 9) levels. In the second-line treatment with gemcitabine plus nab-paclitaxel, the median PFS was 5.1 months (95% CI, 4.6 to 6.0), and the median OS was 8.6 months (95% CI, 7.3 to 10.0). Median PFS was 6.6 months in patients with normal CEA levels compared to 4.4 months in patients with high CEA levels (P = 0.01). Median PFS was 6 months in patients with ECOG PS 0–1 compared to 3.8 months in patients with PS 2 (P < 0.01). This study demonstrates the contribution of gemcitabine plus nab-paclitaxel in both OS and PFS in second-line treatment of metastatic pancreatic cancer. It was found to be a good option especially for young patients with good ECOG PS.